N-(pyridin-2-ylmethyl)methanimine | 1546072-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(pyridin-2-ylmethyl)methanimine
• CAS: 1546072-58-5
• 化学式: C₇H₈N₂
• 分子量: 120.154
• InChiKey: BYDHXXMRNTXSSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 (2S,5R,6S)-4-nitrobenzyl 6-((R)-1-hydroxyethyl)-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate 、 N-(pyridin-2-ylmethyl)methanimine 在 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 反应 20.0h， 以58%的产率得到4-nitrobenzyl (1R)-5-[(R)-1-hydroxyethyl]-4,8-dioxo-3-(pyridin-2-ylmethyl)-3,9-diazabicyclo[4.2.1]nonane-1-carboxylate
  参考文献：
  名称：

  碳青霉烯核上的有机催化曼尼希反应 - 曼尼希碱和双环二氮酮的合成

  摘要：

  使用有机催化开发了碳青霉烯曼尼希碱的有效非对映选择性合成。该方法还提供了一条获得具有生物学意义的新型高度官能化二氮杂双环[4.2.1]壬烷的途径。

  DOI：

  10.1002/ejoc.201301823

文献信息

• AMIDE COMPOUND
  申请人：Setoh Masaki

  公开号：US20100041891A1

  公开（公告）日：2010-02-18

  A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive/therapeutic agent for schizophrenia or the like. The compound is represented by the following formula: wherein A represents —CONR a — or —NR a CO—, R a represents a hydrogen atom or the like, B represents a hydrogen atom or the like, a ring Cy1 represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B, a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like, a ring Cy3 represents a five- or six-membered ring which may have one or more substituents; X represents C 1-2 alkylene or the like, m represents an integer of 0 to 2, and a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.

  提供具有GPR52激动剂活性或其盐的化合物。该化合物可作为预防/治疗精神分裂症等疾病的药物。该化合物由以下公式表示：其中A代表—CONRa—或—NRaCO—，Ra代表氢原子或类似物质，B代表氢原子或类似物质，环Cy1代表一个六元芳香环，除了由-A-B表示的基团外，可能有一个或多个取代基，环Cy2代表一个六元环，可能被卤素原子或类似物质取代，环Cy3代表一个有一个或多个取代基的五元或六元环；X代表C1-2烷基或类似物质，m代表0到2之间的整数，环Cy4代表一个六元芳香环，可能有一个或多个取代基。
• ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC DEVICE
  申请人：Idemitsu Kosan Co., Ltd.

  公开号：US20180179206A1

  公开（公告）日：2018-06-28

  A compound represented by formula (1): wherein R 1 to R 8 , R 12 to R 18 , R 21 to R 25 , R 31 to R 48 , L 1 to L 3 , and Ar are as defined in the specification, provides a high performance organic electroluminescence device which comprises a cathode, an anode and an organic layer between the cathode and the anode, wherein the organic layer comprises a light emitting layer and at least one layer of the organic layer comprises the compound.

  由式（1）表示的化合物：其中R1至R8，R12至R18，R21至R25，R31至R48，L1至L3和Ar如规范中定义的那样，提供了一种高性能的有机电致发光器件，该器件包括阴极、阳极和位于阴极与阳极之间的有机层，其中有机层包括发光层，至少有一层有机层包含该化合物。
• Imidazolyl derivatives
  申请人：Thurieau Alain Christophe

  公开号：US20070032653A1

  公开（公告）日：2007-02-08

  The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors.

  本发明涉及公式（I）的咪唑基衍生物，其中置换基在说明书中定义，可用作生长抑素受体的激动剂或拮抗剂。
• ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：Stenkamp Dirk

  公开号：US20090069282A1

  公开（公告）日：2009-03-12

  The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R 1 and R 2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的炔化合物，其中A、B、W、X、Y、Z、R1和R2的基团和残基具有权利要求1中给出的含义。本发明还涉及包含至少一种根据本发明的炔烃的制药组合物。鉴于它们的MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• Pyrazole Derivatives
  申请人：Jones Lyn Howard

  公开号：US20120029192A1

  公开（公告）日：2012-02-02

  This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

  本发明涉及式（I）的吡唑衍生物或其药学上可接受的盐，溶剂或衍生物，以及其制备方法，用于制备中间体的组合物和这些衍生物的用途。本发明的化合物结合酶逆转录酶并且是调节剂，特别是抑制剂。因此，本发明的化合物在治疗包括逆转录酶抑制剂在内的多种疾病方面是有用的。感兴趣的疾病包括由人类免疫缺陷病毒（HIV）和遗传相关逆转录病毒引起的疾病，例如获得性免疫缺陷综合症（AIDS）。